Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups
Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19....
Saved in:
| Published in | Journal of autoimmunity Vol. 125; p. 102744 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.12.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19.
The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle.
The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53–1203) vs 825 (451–1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients.
Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine, while a different type of vaccine could be administered to non-responder individuals.
•Autoimmune systemic diseases (ASD) show impaired immunogenicity to Covid-19 vaccines.•ASD show significantly higher percentage of non-responder patients than controls.•Early neutralizing Ab post-vaccine detection is recommended in immunocompromised patients.•Patients with suboptimal response should be prioritized for a booster-dose of vaccine.•A different type of Covid-19 vaccine could be attempted in non-responder individuals. |
|---|---|
| AbstractList | Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19.
The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle.
The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53–1203) vs 825 (451–1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients.
Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine, while a different type of vaccine could be administered to non-responder individuals.
•Autoimmune systemic diseases (ASD) show impaired immunogenicity to Covid-19 vaccines.•ASD show significantly higher percentage of non-responder patients than controls.•Early neutralizing Ab post-vaccine detection is recommended in immunocompromised patients.•Patients with suboptimal response should be prioritized for a booster-dose of vaccine.•A different type of Covid-19 vaccine could be attempted in non-responder individuals. Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19. The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle. The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53–1203) vs 825 (451–1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients. Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine, while a different type of vaccine could be administered to non-responder individuals. Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19. The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle. The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53-1203) vs 825 (451-1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients. Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine, while a different type of vaccine could be administered to non-responder individuals.Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19. The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle. The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53-1203) vs 825 (451-1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients. Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine, while a different type of vaccine could be administered to non-responder individuals. Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19. The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle. The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53-1203) vs 825 (451-1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients. Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine, while a different type of vaccine could be administered to non-responder individuals. |
| ArticleNumber | 102744 |
| Author | Caminiti, Rodolfo Raimondo, Vincenzo Brittelli, Raffaele Olivo, Domenico Gigliotti, Pietro Pigatto, Erika Pagano Mariano, Giuseppa Monti, Monica Dal Bosco, Ylenia Aiello, Vincenzo Cacciapaglia, Fabio Pellegrini, Roberta Ferri, Clodoveo Cozzi, Franco Rechichi, Giovanni Foti, Rosario Antonelli, Alessandro Urraro, Teresa Ursini, Francesco Caminiti, Maurizio Cavazzana, Ilaria Zignego, Anna Linda Ferrari, Tommaso Fallahi, Poupak Gragnani, Laura Amato, Giorgio Iannone, Florenzo Giacomelli, Roberto Puccetti, Lorenzo Spinella, Amelia Visalli, Elisa Naclerio, Caterina Vadacca, Marta Santini, Stefano Angelo Franceschini, Franco Giuggioli, Dilia Varcasia, Giuseppe Scorpiniti, Daniela Visentini, Marcella Elia, Giusy Casato, Milvia Ruscitti, Piero Cuomo, Giovanna L'Andolina, Massimo Meliconi, Riccardo Tavoni, Antonio Masini, Francesco La Gualana, Francesca |
| Author_xml | – sequence: 1 givenname: Clodoveo surname: Ferri fullname: Ferri, Clodoveo email: clferri@unimore.it organization: Rheumatology Unit, University of Modena and Reggio Emilia, School of Medicine, Modena, Italy – sequence: 2 givenname: Francesco orcidid: 0000-0001-8194-8642 surname: Ursini fullname: Ursini, Francesco organization: Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy – sequence: 3 givenname: Laura orcidid: 0000-0001-6800-9149 surname: Gragnani fullname: Gragnani, Laura organization: MASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence Center, Center for Research and Innovation CRIA-MASVE, Firenze, Italy – sequence: 4 givenname: Vincenzo surname: Raimondo fullname: Raimondo, Vincenzo organization: Rheumatology Clinic ‘Madonna Dello Scoglio’ Cotronei, Crotone, Italy – sequence: 5 givenname: Dilia surname: Giuggioli fullname: Giuggioli, Dilia organization: Rheumatology Unit, University of Modena and Reggio Emilia, School of Medicine, Modena, Italy – sequence: 6 givenname: Rosario surname: Foti fullname: Foti, Rosario organization: Rheumatology Unit AOU Policlinico G. Rodolico - S. Marco, Catania. Italy – sequence: 7 givenname: Maurizio surname: Caminiti fullname: Caminiti, Maurizio organization: UOD Reumatologia- Grande Ospedale Metropolitano, Reggio Calabria, Italy – sequence: 8 givenname: Domenico surname: Olivo fullname: Olivo, Domenico organization: Rheumatology Outpatient Clinic, San Giovanni di Dio Hospital, Crotone, Italy – sequence: 9 givenname: Giovanna surname: Cuomo fullname: Cuomo, Giovanna organization: University of Campania Luigi Vanvitelli, Department of Precision Medicine, Napoli, Italy – sequence: 10 givenname: Marcella surname: Visentini fullname: Visentini, Marcella organization: Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy – sequence: 11 givenname: Fabio surname: Cacciapaglia fullname: Cacciapaglia, Fabio organization: UO Reumatologia – DETO, Università di Bari, Bari, Italy – sequence: 12 givenname: Roberta surname: Pellegrini fullname: Pellegrini, Roberta organization: U.O.C. Medicina Interna “M.Valentini” P.O. Annunziata, Cosenza, Italy – sequence: 13 givenname: Erika surname: Pigatto fullname: Pigatto, Erika organization: Ospedale “Villa Salus”, Mestre, Italy – sequence: 14 givenname: Teresa orcidid: 0000-0001-9832-9629 surname: Urraro fullname: Urraro, Teresa organization: Rheumatology Unit, “M. Scarlato” Hospital, Scafati, SA, Italy – sequence: 15 givenname: Caterina surname: Naclerio fullname: Naclerio, Caterina organization: Rheumatology Unit, “M. Scarlato” Hospital, Scafati, SA, Italy – sequence: 16 givenname: Antonio surname: Tavoni fullname: Tavoni, Antonio organization: Clinical Immunology, University of Pisa, Pisa, Italy – sequence: 17 givenname: Lorenzo surname: Puccetti fullname: Puccetti, Lorenzo organization: Clinical Immunology, University of Pisa, Pisa, Italy – sequence: 18 givenname: Giuseppe surname: Varcasia fullname: Varcasia, Giuseppe organization: U.O.S. Reumatologia, Ospedale Castrovillari, Cosenza, Italy – sequence: 19 givenname: Ilaria surname: Cavazzana fullname: Cavazzana, Ilaria organization: Rheumatology, Spedali Civili di Brescia, Brescia, Italy – sequence: 20 givenname: Massimo surname: L'Andolina fullname: L'Andolina, Massimo organization: Rheumatology Outpatient Clinic, ASP- Vibo Valentia–Tropea Hospital, Italy – sequence: 21 givenname: Piero surname: Ruscitti fullname: Ruscitti, Piero organization: Rheumatology Unit, Department of Biotechnological & Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy – sequence: 22 givenname: Marta surname: Vadacca fullname: Vadacca, Marta organization: Unità Operativa di Immunoreumatologia-Area Medicina Clinica Policlinico Universitario Campus Bio-Medico di Roma, Roma, Italy – sequence: 23 givenname: Pietro surname: Gigliotti fullname: Gigliotti, Pietro organization: U.O.T. Specialistica Ambulatoriale, ASP 201, Cosenza, Italy – sequence: 24 givenname: Francesca surname: La Gualana fullname: La Gualana, Francesca organization: Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy – sequence: 25 givenname: Franco surname: Cozzi fullname: Cozzi, Franco organization: Ospedale “Villa Salus”, Mestre, Italy – sequence: 26 givenname: Amelia surname: Spinella fullname: Spinella, Amelia organization: Rheumatology Unit, University of Modena and Reggio Emilia, School of Medicine, Modena, Italy – sequence: 27 givenname: Elisa surname: Visalli fullname: Visalli, Elisa organization: Rheumatology Unit AOU Policlinico G. Rodolico - S. Marco, Catania. Italy – sequence: 28 givenname: Ylenia surname: Dal Bosco fullname: Dal Bosco, Ylenia organization: Rheumatology Unit AOU Policlinico G. Rodolico - S. Marco, Catania. Italy – sequence: 29 givenname: Giorgio surname: Amato fullname: Amato, Giorgio organization: Rheumatology Unit AOU Policlinico G. Rodolico - S. Marco, Catania. Italy – sequence: 30 givenname: Francesco surname: Masini fullname: Masini, Francesco organization: University of Campania Luigi Vanvitelli, Department of Precision Medicine, Napoli, Italy – sequence: 31 givenname: Giuseppa surname: Pagano Mariano fullname: Pagano Mariano, Giuseppa organization: UOD Reumatologia- Grande Ospedale Metropolitano, Reggio Calabria, Italy – sequence: 32 givenname: Raffaele surname: Brittelli fullname: Brittelli, Raffaele organization: Rheumatology Clinic ‘Madonna Dello Scoglio’ Cotronei, Crotone, Italy – sequence: 33 givenname: Vincenzo orcidid: 0000-0002-8564-6569 surname: Aiello fullname: Aiello, Vincenzo organization: Rheumatology Clinic ‘Madonna Dello Scoglio’ Cotronei, Crotone, Italy – sequence: 34 givenname: Rodolfo surname: Caminiti fullname: Caminiti, Rodolfo organization: Rheumatology Clinic ‘Madonna Dello Scoglio’ Cotronei, Crotone, Italy – sequence: 35 givenname: Daniela surname: Scorpiniti fullname: Scorpiniti, Daniela organization: Rheumatology Clinic ‘Madonna Dello Scoglio’ Cotronei, Crotone, Italy – sequence: 36 givenname: Giovanni surname: Rechichi fullname: Rechichi, Giovanni organization: Rheumatology Clinic ‘Madonna Dello Scoglio’ Cotronei, Crotone, Italy – sequence: 37 givenname: Tommaso surname: Ferrari fullname: Ferrari, Tommaso organization: U.O.S. Reumatologia, Ospedale Castrovillari, Cosenza, Italy – sequence: 38 givenname: Monica surname: Monti fullname: Monti, Monica organization: MASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence Center, Center for Research and Innovation CRIA-MASVE, Firenze, Italy – sequence: 39 givenname: Giusy orcidid: 0000-0002-7280-2200 surname: Elia fullname: Elia, Giusy organization: Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, School of Medicine, Pisa, Italy – sequence: 40 givenname: Franco surname: Franceschini fullname: Franceschini, Franco organization: Rheumatology, Spedali Civili di Brescia, Brescia, Italy – sequence: 41 givenname: Riccardo surname: Meliconi fullname: Meliconi, Riccardo organization: Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy – sequence: 42 givenname: Milvia surname: Casato fullname: Casato, Milvia organization: Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy – sequence: 43 givenname: Florenzo surname: Iannone fullname: Iannone, Florenzo organization: UO Reumatologia – DETO, Università di Bari, Bari, Italy – sequence: 44 givenname: Roberto surname: Giacomelli fullname: Giacomelli, Roberto organization: Unità Operativa di Immunoreumatologia-Area Medicina Clinica Policlinico Universitario Campus Bio-Medico di Roma, Roma, Italy – sequence: 45 givenname: Poupak orcidid: 0000-0002-5455-4186 surname: Fallahi fullname: Fallahi, Poupak organization: Department of Translational Research & New Technologies in Medicine and Surgery, University of Pisa, School of Medicine, Pisa, Italy – sequence: 46 givenname: Stefano Angelo orcidid: 0000-0003-1956-5899 surname: Santini fullname: Santini, Stefano Angelo organization: Department of Basic, Clinical, Intensive and Perioperative Biotechnological Sciences, Catholic University School of Medicine, Rome, Italy – sequence: 47 givenname: Anna Linda surname: Zignego fullname: Zignego, Anna Linda organization: MASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence Center, Center for Research and Innovation CRIA-MASVE, Firenze, Italy – sequence: 48 givenname: Alessandro orcidid: 0000-0002-5211-6342 surname: Antonelli fullname: Antonelli, Alessandro organization: Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, School of Medicine, Pisa, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34781162$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks9u1DAQxi1URLeFF-CAfOSSxfbGiY0QElr-dKVKvQBXy7EnWy-JHexkpb3xCFx5PZ4Eh20R9FBOI9nf75vRfHOGTnzwgNBTSpaU0OrFbrnT07hkhNH8wOqyfIAWlEheSMrrE7QgQlaFKCk9RWcp7QihlHP-CJ2uylpQWrEF-r7pB-0iWOz6fvJhC94ZNx7wGPD66vPmbUEl3mtjnIeEnce5Y_gtBZwOaYTeGWxdAp0gLfGF217jIcJed-AN4NDiPHQRIQ3BJ5gNrGtbiOBHPOjR5Zp-fvuB09RsY5iG9Bg9bHWX4MlNPUef3r_7uL4oLq8-bNZvLgvDSTUWWlaC6hU0llveNKSVHEizkhWlljPWcqvLUthSUiiZrsSKSV61tjRVSyrN9eocvT76DlPTgzV5kKg7NUTX63hQQTv1749312ob9krwupaSZoPnNwYxfJ0gjap3yUDXaQ9hSopxKUgtGJFZ-uzvXn-a3MaQBeIoMDGkFKFVOYO8nTC3dp2iRM2Jq52aE1dz4uqYeEbZHfTW_V7o1RGCvOG9g6iScXNgNp-CGZUN7n785R3cdC7fje6-wOF_8C-c3tyx |
| CitedBy_id | crossref_primary_10_1002_acr_25221 crossref_primary_10_1111_bjh_18578 crossref_primary_10_1093_rheumatology_kead449 crossref_primary_10_3899_jrheum_2023_1214 crossref_primary_10_1007_s10238_023_01163_5 crossref_primary_10_1007_s11926_023_01110_z crossref_primary_10_1002_iid3_858 crossref_primary_10_1002_ctm2_1497 crossref_primary_10_1111_1756_185X_14713 crossref_primary_10_1038_s41590_022_01130_4 crossref_primary_10_3390_vaccines11040874 crossref_primary_10_1371_journal_pone_0303420 crossref_primary_10_1016_j_ccm_2022_11_013 crossref_primary_10_3390_idr15010003 crossref_primary_10_3389_fimmu_2023_1185278 crossref_primary_10_1038_s41598_022_11857_7 crossref_primary_10_3390_v15091968 crossref_primary_10_3389_fimmu_2023_1103196 crossref_primary_10_3899_jrheum_220469 crossref_primary_10_37489_0235_2990_2022_67_5_6_70_80 crossref_primary_10_1038_s41598_022_22839_0 crossref_primary_10_3390_jpm12091420 crossref_primary_10_1007_s00296_024_05682_6 crossref_primary_10_1172_jci_insight_180750 crossref_primary_10_26442_20751753_2023_2_202142 crossref_primary_10_1016_j_jaut_2022_102846 crossref_primary_10_1080_14787210_2022_2072296 crossref_primary_10_3389_fimmu_2022_988004 crossref_primary_10_3899_jrheum_211152 crossref_primary_10_3899_jrheum_211270 crossref_primary_10_3390_biomedicines10112674 crossref_primary_10_1039_D1NR03831A crossref_primary_10_1177_09612033221151012 crossref_primary_10_3390_biomedicines10040834 crossref_primary_10_1093_bjd_ljac045 crossref_primary_10_1136_ard_2022_223559 crossref_primary_10_1177_17562864221141505 crossref_primary_10_2174_1381612828666220614151732 crossref_primary_10_3389_fimmu_2023_1296148 crossref_primary_10_3389_fimmu_2022_846753 crossref_primary_10_1007_s00296_024_05734_x crossref_primary_10_2139_ssrn_4133614 crossref_primary_10_3390_vaccines13020104 crossref_primary_10_3389_fpubh_2023_1245464 crossref_primary_10_1016_S2665_9913_22_00100_X crossref_primary_10_1038_s41541_022_00568_9 crossref_primary_10_1016_S2665_9913_22_00130_8 crossref_primary_10_3390_v14081766 crossref_primary_10_3390_v15030620 crossref_primary_10_1016_j_jtauto_2022_100164 crossref_primary_10_12680_balneo_2022_562 crossref_primary_10_1016_j_jinf_2024_106288 crossref_primary_10_1186_s13223_023_00791_6 crossref_primary_10_1007_s11739_022_03028_3 crossref_primary_10_1097_CM9_0000000000002505 crossref_primary_10_1136_bmjresp_2022_001268 crossref_primary_10_1055_s_0043_1768921 crossref_primary_10_1136_rmdopen_2023_003250 crossref_primary_10_63032_MNQF7735 crossref_primary_10_1186_s40001_023_01620_7 crossref_primary_10_1007_s10067_022_06227_7 crossref_primary_10_1016_j_rdc_2024_09_006 crossref_primary_10_1080_1744666X_2022_2044797 crossref_primary_10_1016_j_cellimm_2024_104883 crossref_primary_10_1007_s10787_022_01089_6 crossref_primary_10_1016_j_rdc_2023_01_012 crossref_primary_10_3390_vaccines12010100 crossref_primary_10_1093_ofid_ofaf021 crossref_primary_10_3390_vaccines11091456 crossref_primary_10_1093_rheumatology_keac604 crossref_primary_10_1016_j_jtauto_2023_100212 crossref_primary_10_1136_rmdopen_2022_002479 crossref_primary_10_1136_rmdopen_2022_002798 crossref_primary_10_1016_j_jaut_2022_102866 crossref_primary_10_1136_rmdopen_2022_002871 crossref_primary_10_14412_1996_7012_2022_2_7_12 crossref_primary_10_1007_s10238_022_00808_1 crossref_primary_10_1007_s10875_023_01444_4 crossref_primary_10_1136_rmdopen_2023_003022 crossref_primary_10_3390_ijms252011149 crossref_primary_10_3389_fimmu_2022_919958 crossref_primary_10_3390_tropicalmed8020109 crossref_primary_10_3390_vaccines10040557 crossref_primary_10_1007_s11060_021_03911_7 crossref_primary_10_1038_s41598_022_18996_x crossref_primary_10_1007_s10067_022_06219_7 crossref_primary_10_12680_balneo_2023_562 crossref_primary_10_1093_rheumatology_keac241 crossref_primary_10_46497_ArchRheumatol_2023_9676 crossref_primary_10_1016_j_ejim_2022_11_009 crossref_primary_10_1016_j_rdc_2023_03_007 crossref_primary_10_1016_j_arcmed_2024_103141 |
| Cites_doi | 10.1136/annrheumdis-2020-218296 10.1016/S2665-9913(21)00007-2 10.7326/M21-1451 10.2174/1381612827666210903103935 10.1016/S2665-9913(21)00247-2 10.1136/annrheumdis-2021-220272 10.1136/annrheumdis-2020-217871 10.1136/annrheumdis-2021-220503 10.1136/annrheumdis-2021-220647 10.3390/biomedicines9091163 10.1002/acr2.11299 10.1136/annrheumdis-2021-220834 10.1136/annrheumdis-2021-220656 10.1016/S2665-9913(21)00282-4 10.1136/rmdopen-2020-001464 10.1136/annrheumdis-2021-220604 10.1136/annrheumdis-2020-217984 10.1002/art.41619 10.1016/S2665-9913(21)00243-5 10.1016/S2665-9913(21)00251-4 10.1007/s10067-020-05334-7 10.1016/S2665-9913(21)00186-7 10.1136/annrheumdis-2021-220408 10.1136/annrheumdis-2021-220289 |
| ContentType | Journal Article |
| Copyright | 2021 Elsevier Ltd Copyright © 2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd |
| Copyright_xml | – notice: 2021 Elsevier Ltd – notice: Copyright © 2021 Elsevier Ltd. All rights reserved. – notice: 2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.jaut.2021.102744 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1095-9157 |
| EndPage | 102744 |
| ExternalDocumentID | PMC8577991 34781162 10_1016_j_jaut_2021_102744 S0896841121001529 |
| Genre | Multicenter Study Journal Article Observational Study |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFRF ABJNI ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DM4 DU5 EBS EFBJH EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDU HMG HMK HMO HVGLF HZ~ IHE J1W KOM LG5 LUGTX LZ5 M29 M41 MO0 N9A O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SES SEW SIN SPCBC SSH SSI SSZ T5K WUQ XPP Z5R ZGI ZMT ZU3 ~G- AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EFLBG LCYCR RIG AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c506t-a9681a3ebd5d5bb0f95e0b39611d522f5da448d491e42a6832956fd4c6f06a5a3 |
| IEDL.DBID | .~1 |
| ISSN | 0896-8411 1095-9157 |
| IngestDate | Thu Aug 21 18:25:41 EDT 2025 Fri Jul 11 00:27:17 EDT 2025 Thu Apr 03 07:06:43 EDT 2025 Thu Apr 24 23:00:55 EDT 2025 Tue Jul 01 03:24:11 EDT 2025 Fri Feb 23 02:41:52 EST 2024 Tue Aug 26 18:13:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | World Health Organization Neutralizing antibodies Systemic lupus Autoimmune systemic diseases Neutralizing antibody Rheumatoid factor Anti-citrullinated protein antibodies Systemic lupus erythematosus Adverse events Systemic sclerosis Rheumatoid arthritis Binding Antibody Units COVID-19 vaccine Systemic vasculitis Cryoglobulinemic vasculitis |
| Language | English |
| License | Copyright © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c506t-a9681a3ebd5d5bb0f95e0b39611d522f5da448d491e42a6832956fd4c6f06a5a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-5455-4186 0000-0002-8564-6569 0000-0002-7280-2200 0000-0001-8194-8642 0000-0003-1956-5899 0000-0001-6800-9149 0000-0002-5211-6342 0000-0001-9832-9629 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8577991 |
| PMID | 34781162 |
| PQID | 2598078209 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8577991 proquest_miscellaneous_2598078209 pubmed_primary_34781162 crossref_citationtrail_10_1016_j_jaut_2021_102744 crossref_primary_10_1016_j_jaut_2021_102744 elsevier_sciencedirect_doi_10_1016_j_jaut_2021_102744 elsevier_clinicalkey_doi_10_1016_j_jaut_2021_102744 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-01 |
| PublicationDateYYYYMMDD | 2021-12-01 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of autoimmunity |
| PublicationTitleAlternate | J Autoimmun |
| PublicationYear | 2021 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | D'Amelio, Asero, Cassatella, Laganà, Lunardi, Migliorini (bib12) 2021; 9 Rubbert-Roth, Vuilleumier, Ludewig, Schmiedeberg, Haller, von Kempis (bib20) 2021; 3 Ferri, Giuggioli, Raimondo, Dagna, Riccieri, Zanatta (bib8) 2021; 3 Hasseli, Mueller-Ladner, Hoyer, Krause, Lorenz, Pfeil (bib11) 2021; 7 Freites Nuñez, Leon, Mucientes, Rodriguez-Rodriguez, Font Urgelles, Madrid García (bib7) 2020; 79 (bib18) 2018 Simon, Tascilar, Schmidt, Manger, Weckwerth, Sokolova (bib27) 2021 Geisen, Berner, Tran, Sümbül, Vullriede, Ciripoi (bib13) 2021; 80 Izmirly, Kim, Samanovic, Fernandez-Ruiz, Ohana, Deonaraine (bib23) 2021 Frey, Connolly, Chiang, Teles, Alejo, Boyarsky (bib29) 2021; 3 D'Silva, Jorge, Cohen, McCormick, Zhang, Wallace (bib2) 2021; 73 Moor, Suter-Riniker, Horn, Aeberli, Amsler, Möller (bib26) 2021 Furer, Eviatar, Zisman, Peleg, Paran, Levartovsky (bib16) 2021; 80 Ferri, Giuggioli, Raimondo, L'Andolina, Tavoni, Cecchetti (bib3) 2020; 39 Spiera, Jinich, Jannat-Khah (bib25) 2021; 80 contributors (bib10) 2020 Albach, Burmester, Biesen (bib31) 2021; 80 Bixio, Bertelle, Masia, Pistillo, Carletto, Rossini (bib28) 2021 Fagni, Simon, Tascilar, Schoenau, Sticherling, Neurath (bib5) 2021; 3 Boekel, Steenhuis, Hooijberg, Besten, van Kempen, Kummer (bib19) 2021 Ammitzbøll, Bartels, Bøgh Andersen, Risbøl Vils, Elbaek Mistegård, Dahl Johannsen (bib22) 2021; 3 Connolly, Teles, Frey, Boyarsky, Alejo, Werbel (bib30) 2021 Gianfrancesco, Hyrich, Al-Adely, Carmona, Danila, Gossec (bib9) 2020; 79 Braun-Moscovici, Kaplan, Braun, Markovits, Giryes, Toledano (bib15) 2021; 80 Pablos, Galindo, Carmona, Lledó, Retuerto, Blanco (bib1) 2020; 79 Antonelli, Fallahi, Elia, Ragusa, Paparo, Mazzi (bib4) 2021; 3 Boyarsky, Ruddy, Connolly, Ou, Werbel, Garonzik-Wang (bib17) 2021 Ruddy, Connolly, Boyarsky, Werbel, Christopher-Stine, Garonzik-Wang (bib14) 2021; 80 Connolly, Boyarsky, Ruddy, Werbel, Christopher-Stine, Garonzik-Wang (bib21) 2021; 174 Bonelli, Mrak, Perkmann, Haslacher, Aletaha (bib24) 2021; 80 Ferri, Giuggioli, Raimondo, L'Andolina, Dagna, Tavoni (bib6) 2021 Boekel (10.1016/j.jaut.2021.102744_bib19) 2021 Ammitzbøll (10.1016/j.jaut.2021.102744_bib22) 2021; 3 Gianfrancesco (10.1016/j.jaut.2021.102744_bib9) 2020; 79 Izmirly (10.1016/j.jaut.2021.102744_bib23) 2021 Connolly (10.1016/j.jaut.2021.102744_bib30) 2021 contributors (10.1016/j.jaut.2021.102744_bib10) 2020 Hasseli (10.1016/j.jaut.2021.102744_bib11) 2021; 7 Connolly (10.1016/j.jaut.2021.102744_bib21) 2021; 174 Boyarsky (10.1016/j.jaut.2021.102744_bib17) 2021 Geisen (10.1016/j.jaut.2021.102744_bib13) 2021; 80 Moor (10.1016/j.jaut.2021.102744_bib26) 2021 Furer (10.1016/j.jaut.2021.102744_bib16) 2021; 80 Ruddy (10.1016/j.jaut.2021.102744_bib14) 2021; 80 Ferri (10.1016/j.jaut.2021.102744_bib8) 2021; 3 Braun-Moscovici (10.1016/j.jaut.2021.102744_bib15) 2021; 80 Bonelli (10.1016/j.jaut.2021.102744_bib24) 2021; 80 Pablos (10.1016/j.jaut.2021.102744_bib1) 2020; 79 D'Silva (10.1016/j.jaut.2021.102744_bib2) 2021; 73 Antonelli (10.1016/j.jaut.2021.102744_bib4) 2021; 3 Ferri (10.1016/j.jaut.2021.102744_bib3) 2020; 39 Bixio (10.1016/j.jaut.2021.102744_bib28) 2021 Fagni (10.1016/j.jaut.2021.102744_bib5) 2021; 3 Ferri (10.1016/j.jaut.2021.102744_bib6) 2021 D'Amelio (10.1016/j.jaut.2021.102744_bib12) 2021; 9 (10.1016/j.jaut.2021.102744_bib18) 2018 Spiera (10.1016/j.jaut.2021.102744_bib25) 2021; 80 Frey (10.1016/j.jaut.2021.102744_bib29) 2021; 3 Freites Nuñez (10.1016/j.jaut.2021.102744_bib7) 2020; 79 Simon (10.1016/j.jaut.2021.102744_bib27) 2021 Albach (10.1016/j.jaut.2021.102744_bib31) 2021; 80 Rubbert-Roth (10.1016/j.jaut.2021.102744_bib20) 2021; 3 |
| References_xml | – volume: 73 start-page: 914 year: 2021 end-page: 920 ident: bib2 article-title: COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study publication-title: Arthritis Rheum. – year: 2021 ident: bib17 article-title: Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases publication-title: Ann. Rheum. Dis. – volume: 174 start-page: 1332 year: 2021 end-page: 1334 ident: bib21 article-title: Absence of humoral response after two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases: a case series publication-title: Ann. Intern. Med. – year: 2021 ident: bib28 article-title: Incidence of Disease Flare after BNT162b2 Coronavirus Disease 2019 Vaccination in Patients with Rheumatoid Arthritis in Remission – volume: 79 start-page: 1393 year: 2020 end-page: 1399 ident: bib7 article-title: Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases publication-title: Ann. Rheum. Dis. – volume: 80 start-page: 1306 year: 2021 end-page: 1311 ident: bib13 article-title: Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort publication-title: Ann. Rheum. Dis. – year: 2018 ident: bib18 publication-title: EULAR Compendium on Rheumatic Diseases – volume: 3 start-page: 622 year: 2021 end-page: 628 ident: bib22 article-title: Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis publication-title: ACR Open Rheumatol – year: 2021 ident: bib27 article-title: Brief Report: Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in B Cell Depleted Autoimmune Patients – volume: 80 start-page: 1355 year: 2021 end-page: 1356 ident: bib24 article-title: SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response publication-title: Ann. Rheum. Dis. – volume: 3 start-page: e470 year: 2021 end-page: e472 ident: bib20 article-title: Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis publication-title: Lancet Rheumatol – volume: 3 start-page: e753 year: 2021 end-page: e754 ident: bib29 article-title: Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination publication-title: Lancet Rheumatol – volume: 9 year: 2021 ident: bib12 article-title: Anti-COVID-19 vaccination in patients with autoimmune-autoinflammatory disorders and primary/secondary immunodeficiencies: the position of the task force on behalf of the Italian immunological societies publication-title: Biomedicines – volume: 7 year: 2021 ident: bib11 article-title: Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases publication-title: RMD Open – volume: 80 start-page: 1357 year: 2021 end-page: 1359 ident: bib25 article-title: Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases publication-title: Ann. Rheum. Dis. – year: 2021 ident: bib6 article-title: Covid-19 and rheumatic autoimmune systemic diseases: role of pre-existing lung involvement and ongoing treatments publication-title: Curr. Pharmaceut. Des. – year: 2021 ident: bib26 article-title: Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study publication-title: Lancet Rheumatol – year: 2020 ident: bib10 article-title: Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients publication-title: Ann. Rheum. Dis. – volume: 3 start-page: e724 year: 2021 end-page: e736 ident: bib5 article-title: COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses publication-title: Lancet Rheumatol – volume: 79 start-page: 1544 year: 2020 end-page: 1549 ident: bib1 article-title: Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study publication-title: Ann. Rheum. Dis. – volume: 80 start-page: 1317 year: 2021 end-page: 1321 ident: bib15 article-title: Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2 publication-title: Ann. Rheum. Dis. – volume: 3 start-page: e166 year: 2021 end-page: e168 ident: bib8 article-title: COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study publication-title: Lancet Rheumatol – volume: 79 start-page: 859 year: 2020 end-page: 866 ident: bib9 article-title: Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry publication-title: Ann. Rheum. Dis. – volume: 80 start-page: 1330 year: 2021 end-page: 1338 ident: bib16 article-title: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study publication-title: Ann. Rheum. Dis. – year: 2021 ident: bib19 article-title: Antibody development after COVID-19 vaccination in patients with autoimmune diseases in The Netherlands: a substudy of data from two prospective cohort studies publication-title: Lancet Rheumatol – year: 2021 ident: bib30 article-title: Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series publication-title: Ann. Rheum. Dis. – volume: 80 start-page: 1361 year: 2021 end-page: 1362 ident: bib31 article-title: Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response publication-title: Ann. Rheum. Dis. – volume: 80 start-page: 1351 year: 2021 end-page: 1352 ident: bib14 article-title: High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases publication-title: Ann. Rheum. Dis. – year: 2021 ident: bib23 article-title: Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination – volume: 39 start-page: 3195 year: 2020 end-page: 3204 ident: bib3 article-title: COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series publication-title: Clin. Rheumatol. – volume: 3 start-page: e675 year: 2021 end-page: e676 ident: bib4 article-title: Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases publication-title: Lancet Rheumatol – volume: 79 start-page: 1544 year: 2020 ident: 10.1016/j.jaut.2021.102744_bib1 article-title: Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-218296 – volume: 3 start-page: e166 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib8 article-title: COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00007-2 – volume: 174 start-page: 1332 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib21 article-title: Absence of humoral response after two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases: a case series publication-title: Ann. Intern. Med. doi: 10.7326/M21-1451 – year: 2021 ident: 10.1016/j.jaut.2021.102744_bib6 article-title: Covid-19 and rheumatic autoimmune systemic diseases: role of pre-existing lung involvement and ongoing treatments publication-title: Curr. Pharmaceut. Des. doi: 10.2174/1381612827666210903103935 – volume: 3 start-page: e724 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib5 article-title: COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00247-2 – volume: 80 start-page: 1306 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib13 article-title: Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-220272 – volume: 79 start-page: 859 year: 2020 ident: 10.1016/j.jaut.2021.102744_bib9 article-title: Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-217871 – volume: 80 start-page: 1317 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib15 article-title: Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-220503 – year: 2021 ident: 10.1016/j.jaut.2021.102744_bib28 – volume: 80 start-page: 1330 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib16 article-title: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-220647 – volume: 9 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib12 article-title: Anti-COVID-19 vaccination in patients with autoimmune-autoinflammatory disorders and primary/secondary immunodeficiencies: the position of the task force on behalf of the Italian immunological societies publication-title: Biomedicines doi: 10.3390/biomedicines9091163 – volume: 3 start-page: 622 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib22 article-title: Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis publication-title: ACR Open Rheumatol doi: 10.1002/acr2.11299 – volume: 80 start-page: 1361 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib31 article-title: Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-220834 – volume: 80 start-page: 1351 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib14 article-title: High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-220656 – volume: 3 start-page: e753 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib29 article-title: Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00282-4 – year: 2021 ident: 10.1016/j.jaut.2021.102744_bib30 article-title: Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series publication-title: Ann. Rheum. Dis. – year: 2018 ident: 10.1016/j.jaut.2021.102744_bib18 – year: 2021 ident: 10.1016/j.jaut.2021.102744_bib27 – volume: 7 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib11 article-title: Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases publication-title: RMD Open doi: 10.1136/rmdopen-2020-001464 – volume: 80 start-page: 1357 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib25 article-title: Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-220604 – year: 2021 ident: 10.1016/j.jaut.2021.102744_bib19 article-title: Antibody development after COVID-19 vaccination in patients with autoimmune diseases in The Netherlands: a substudy of data from two prospective cohort studies publication-title: Lancet Rheumatol – volume: 79 start-page: 1393 year: 2020 ident: 10.1016/j.jaut.2021.102744_bib7 article-title: Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2020-217984 – volume: 73 start-page: 914 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib2 article-title: COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study publication-title: Arthritis Rheum. doi: 10.1002/art.41619 – volume: 3 start-page: e675 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib4 article-title: Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00243-5 – year: 2021 ident: 10.1016/j.jaut.2021.102744_bib26 article-title: Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00251-4 – volume: 39 start-page: 3195 year: 2020 ident: 10.1016/j.jaut.2021.102744_bib3 article-title: COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series publication-title: Clin. Rheumatol. doi: 10.1007/s10067-020-05334-7 – year: 2020 ident: 10.1016/j.jaut.2021.102744_bib10 article-title: Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients publication-title: Ann. Rheum. Dis. – year: 2021 ident: 10.1016/j.jaut.2021.102744_bib23 – volume: 3 start-page: e470 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib20 article-title: Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00186-7 – volume: 80 start-page: 1355 year: 2021 ident: 10.1016/j.jaut.2021.102744_bib24 article-title: SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-220408 – year: 2021 ident: 10.1016/j.jaut.2021.102744_bib17 article-title: Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2021-220289 |
| SSID | ssj0011555 |
| Score | 2.5984392 |
| Snippet | Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 102744 |
| SubjectTerms | 2019-nCoV Vaccine mRNA-1273 - immunology Antibodies, Neutralizing - blood Antibodies, Viral - blood Autoimmune Diseases - blood Autoimmune Diseases - immunology Autoimmune systemic diseases BNT162 Vaccine - immunology COVID-19 - prevention & control COVID-19 vaccine Cryoglobulinemic vasculitis Female Humans Italy Lupus Erythematosus, Systemic - immunology Male Middle Aged Neutralizing antibodies Prospective Studies Rheumatoid arthritis SARS-CoV-2 - immunology Scleroderma, Systemic - immunology Systemic lupus Systemic sclerosis Systemic vasculitis Systemic Vasculitis - immunology Vaccination Vaccine Potency |
| Title | Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0896841121001529 https://dx.doi.org/10.1016/j.jaut.2021.102744 https://www.ncbi.nlm.nih.gov/pubmed/34781162 https://www.proquest.com/docview/2598078209 https://pubmed.ncbi.nlm.nih.gov/PMC8577991 |
| Volume | 125 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIhAXBOW1PCojcUPpxhs7j2O1UO2CWg5Q1Jtlx45IhZLVJovUS9WfwJW_xy9hxnYiFkSRuO1uxtGsZzwey998Q8hLbg1neWyjXGMLM-4aucc6AufKSquETl159PFJujjlb8_E2Q6ZD7UwCKsMsd_HdBetwy_TMJvTVV1PP8R5keacIQMW7GkzLOLjPEMvP7gcYR6Q8LjOpygcoXQonPEYr3NEicDxnyGDQcb53zanP5PP3zGUv2xKR3fJnZBN0kOv8D2yY5s9ctP3l7zYI7eOw835ffJtCese_qqhNVaEtOA38KS_oH1L5-8_LV9HrKBfVYnSHa0bCjq3TtRSz_ZclzTc5nQHFOEhdLVGrnCcMtpWtGmbaO0RtxZfMLRe6Wngbu1-XH2n3Ua7QpLuATk9evNxvohCN4aoFHHaRwpmm6nEaiOM0DquCmFjnRQpYwaSuEoYBUc9wwtm-UylECng6FUZXqZVnCqhkodkFzSxjwm1ZVJoo0tR6YIbluSQZcBHy-HtPE_MhLDBDLIMVOXYMeOLHDBp5xJNJ9F00ptuQl6NY1aeqONa6WSwrhxKUCFoSthHrh0lxlFbTvrPcS8GB5KwevFKRjW23XQSDp-5oywsJuSRd6hR-8RVAaezCcm2XG0UQGbw7SdN_dkxhOciyyDxf_Kf-j4lt_GbR-08I7v9emOfQ-7V6323uPbJjcPlu8XJTyVEMVk |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEY8LgvLo8jQSnFC6edjZ5MABtVS7tFsOtKg3N44dkapKVpssaC-In8CV38E_4pcwYzsRC6JISL1FsccaecYzY_mbGUKeMa1YkPjaSyS2MGOmkbsvPVCuUa4zLmOTHj09iMdH7M0xP14j37tcGIRVOttvbbqx1u7P0O3mcFaWw3d-ksYJC7ACFvi0MHXIyj29_AT3tublZAeE_DwMd18fbo8911rAy7kft14GpEEWaam44lL6Rcq1L6M0DgIFEUnBVQb3FsXSQLMwi0Ht4R5RKJbHhR9nPItg3UvkMgNzgW0Ttj73uBKIsEyrVeTOQ_Zcpo4FlZ0iLCUEv4olE0aM_c0b_hnt_g7a_MUL7t4kN1z4Sl_ZHbpF1nS1Qa7YhpbLDXJ16p7qb5OvEzA0sLeKlpiCUoOiwki7pG1Nt9--n-x4QUo_ZjnObmhZUeC5NlM1teWly5y656NmiyIehc7mWJwcZUTrglZ15c0txFfjAl2vl5a6YrHNjy_faLOQJnOluUOOLkRGd8k6cKI3CdV5lEolc17IlKkgSiCsgU_NYHWWRGpAgk4MIne10bFFx5noQHCnAkUnUHTCim5AXvQ0M1sZ5NzZUSdd0eW8gpUW4LjOpeI91cqp-Cfd006BBJgLfAPKKl0vGgG33cTUSEwH5J5VqJ77yKQdx-GAjFZUrZ-ApchXR6rygylJnvDRCG4a9_-T3yfk2vhwui_2Jwd7D8h1HLGQoYdkvZ0v9CMI_Fr52Bw0Sk4u-mT_BK44bL0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impaired+immunogenicity+to+COVID-19+vaccines+in+autoimmune+systemic+diseases.+High+prevalence+of+non-response+in+different+patients%27+subgroups&rft.jtitle=Journal+of+autoimmunity&rft.au=Ferri%2C+Clodoveo&rft.au=Ursini%2C+Francesco&rft.au=Gragnani%2C+Laura&rft.au=Raimondo%2C+Vincenzo&rft.date=2021-12-01&rft.issn=1095-9157&rft.eissn=1095-9157&rft.volume=125&rft.spage=102744&rft_id=info:doi/10.1016%2Fj.jaut.2021.102744&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0896-8411&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0896-8411&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0896-8411&client=summon |